

CNS Research, Inc
16 Haliburton Road
East Providence, RI 02916

Phone: 1-800-707-6013
Fax: 1-800-847-4332
Email: norman@cns-research.com

Norman M. Gordon , MD

Certifications

American Board of Independent Medical Examiners - IME's	1997
American Board of Psychiatry and Neurology - Neurology	1992
American Board of Internal Medicine - Internal Medicine	1989
Institute for Aviation Medicine-Pretoria South Africa - Aviation Medicine	1984
VQE Examination	1980
FLEX Examination	1980
ECFMG Exam	1979

Licensure

Primary MD - 07343, Rhode Island

Academic Degrees

MB Bch - Medicine, University of the Witwatersand, Johannesburg, South Africa	1979
Undergraduate - University of the Witwatersand, Johannesburg, South Africa	1976

Residencies and Internships

Resident - Neurology, Rhode Island Hospital-Brown University Neuroscience Department, Providence, RI	1988 - 1991
Chief Resident - Internal Medicine, The Miriam Hospital-Brown University Program in Medicine, Providence, RI	1987 - 1988
Resident - Internal Medicine, The Miriam Hospital-Brown University Program in Medicine, Providence, RI	1985 - 1987
Registrar - Otolaryngology, University of the Witwatersand, Johannesburg, South Africa	1983 - 1983
Registrar - Internal Medicine, University of the Witwatersand, Johannesburg, South Africa	1982 - 1983
Internship - Medicine, Johannesburg Hospital-University of the Witwatersand, Johannesburg, South Africa	1980 - 1980
Internship - Surgery, Hillbrow Hospital-University of the Witwatersand, Johannesburg, South Africa	1980 - 1980

Professional Societies

American Academy of Neurology	present
Rhode Island Neurological Society	present
Rhode Island Medical Society	present

Experience

Medical Director - CNS Research Inc., East Providence, RI	1999 - present
Private Practice of Neurology - Eastside Neurology, East Providence, RI	1991 - present
Medical Director - Providence Research Network, Providence, RI	1999 - 1999
Lieutenant-Medical Officer - The South African Defence Force (Mandatory Military Service)	1984 - 1984
Medical Officer - The South African Defence Force	1981 - 1981

Appointments

Consulting Neurologist - Memory and Cognitive Disorders Clinic, Miriam Hospital, Providence, RI	present
Principal Neurologist - Headache Management Clinic, Miriam Hospital, Providence, RI	present
Preceptor - Outpatient Neurology Clinic, Rhode Island Hospital, Providence, RI	present
Instructor - Neurology, Rhode Island Hospital, Providence, RI	present
Assistant Professor - Clinical Neurosciences, Brown University Medical School, Providence, RI	present
Member - Board of Trustees, New England Organ Bank	present
President - Rhode Island Neurological Society	1997 - 1998
Visiting Professor - University of the Witwatersrand, Johannesburg, South Africa	1996
Assistant Staff Physician - Butler Hospital, Providence, RI	1989 - 1991
Attending Physician - Emergency Department, The Miriam Hospital, Providence, RI	1988 - 1991
Editor - Medical Student's Newspaper, University of the Witwatersrand, Johannesburg, South Africa	1977 - 1978
Treasurer - Medical Student's Council, University of the Witwatersrand, Johannesburg, South Africa	

Current Hospital Affiliations

Butler Hospital - Providence, RI
The Miriam Hospital - Providence, RI
Landmark Medical Center - Woonsocket, RI

Research Affiliations:

CNS Research, Inc	16 Haliburton Road East Providence, RI 02916
CNS Research, Inc.	450 Veterans' Memorial Parkway #11 E. Providence, RI 02914
CNS Research, Inc.	814 Metacom Ave Bristol, RI 02809

Presentations & Publications

Gordon NM, "Migraine and Epilepsy." Regional Speaker, Sponsored by Various Pharmaceutical Companies, 1997 to present.

Gordon NM, "Recent Advances in Headache Management." Co-Director and Faculty, Brown University/Lifespan Regional CME Conference, March 11, 1998.

Gordon NM, Ho G, "Clinoral (Sulindac) Induced Aseptic Meningitis." Presented at the American College of Physicians Annual Resident's Research Meeting, Providence, RI, April 1998.

Gordon NM, "Head Trauma, Migraines and Headache." Consultant and Faculty, Medical and Mental Health Conference Association, National CME Conference, November 19-21, 1998.

Ferrar DJ, Flanigan TP, Gordon NM, et al, "Tuberculous Brain Abscess in a Patient with HIV Infection." Case Report and Review, AM J Med, 102, 1997.

Ott BR, Tate CA, Gordon NM, Heindel WC, "Gender Differences in the Behavioral Manifestations of Alzheimer's Disease." J. Am Geriatric Society, 44: 583-587, May 1996.

Young C, Gordon NM, Safran HP, Schatz S, Stopa E and King TC, "Monoclonal B-Cell Population Mimicking Lymphoma in a Patient with Multiple Sclerosis." Archives of Pathology and Laboratory Medicine, 120: 275-278, March 1996.

"Maintenance Electroconvulsive Therapy in Parkinson's Disease." Accepted for Presentation at the Xith International Symposium on Parkinson's Disease, March 1995.

Feldman E, Gordon NM, "Factors et al: Associated with Early Presentation of Acute Stroke." Stroke, 24: 1805-1810, 1993.

Friedman J, Gordon NM, "Electroconvulsive Therapy in Parkinson's Disease: A Report of Five Cases." Convulsive Therapy, (8) 3: 204-210, 1992.

Gordon NM, Thompson PD, "Cardiac Complication of Recreational Cocain Use." Cardiovascular Reviews and Reports, (8) 2:29-32, 1987.

Alzheimer's Disease Clinical Trials Experience

Protocol AVA102675- REFLECT 4

An open label extension study of the long term safety and efficacy of rosiglitazone extended release tablets as adjunctive therapy to acetylcholinesterase inhibitors in subjects with mild to moderate AD.

Protocol AVA102670

A 54 week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer's Disease.

E2020-G000-326

Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release to 10 mg Donepezil Immediate Release in Patients with Moderate to Severe Alzheimer's Disease.

CL – 758007 Phase III Study of the Efficacy and Safety of Alzhemed in Patients with Mild to Moderate Alzheimer's Disease.

ONO-2506

A Double-blind, Phase II, safety and efficacy evaluation of ONO-2506 in patients with mild to moderate Alzheimer's Disease

Exelon (rivastigmine)

A Prospective, 26-Week, Open-label, Single-arm, Multicenter Study Evaluating the Efficacy and Safety of Exelon (rivastigmine tartrate) in Patients with Mild to Moderate Alzheimer's Disease Who Are Responding Poorly to Aricept (donepezil) Treatment

GAL-INT-26

Johnson & Johnson PRD, GAL-INT-26, A randomized, double-blind, placebo-controlled trial to evaluate the safety & efficacy of galantamine in the treatment of dementia secondary to cerebrovascular disease.

GAL-USA-10

Janssen Research Foundation: GAL-USA-10, A double-blind, placebo-controlled multicenter study of safety and efficacy in Alzheimer's disease.

METRIFONATE

BAYER Corporation: A 26 week multicenter, open label comparison of METRIFONATE to standard therapy in patients with Alzheimer's disease.

MILAMELINE

PARKE-DAVIS: A 26 week, randomized, double-blind, parallel -group, placebo-controlled, multicenter study of MILAMELINE in patients with Alzheimer's disease.

SELEGILINE

SOMERSET PHARMACEUTICALS: A 12 month, double-blind, placebo-controlled, investigation of the safety and efficacy of SELEGILINE Transdermal System in patients with dementias of the Alzheimer's type.

MENTANE

HOECHST PHARMACEUTICALS: A double-blind, multicenter comparison of MENTANE and placebo in outpatients with Alzheimer's disease.

Stroke Clinical Trials Experience

A phase III, randomized, multi-center, open label, 900 subject clinical trial that will examine whether a combined intravenous (IV) and intra-arterial (IA) approach to recanalization is superior to standard IV rt-PA (Activase) alone when initiated within three hours of acute ischemic stroke onset – IMS III – Interventional Management of Stroke

A Randomized, Double-Blind, Placebo-Controlled Study of Viprinex™ (Ancrod Injection) in Subjects Beginning Treatment within 6 Hours of the Onset of Acute, Ischemic Stroke Protocol No.: NTI-ASP-0502

A randomized, double-blind, placebo-controlled, multi-center study of the effects of ONO-2506 intravenous infusion on the amelioration of the neurological damage and improvement of stroke assessment scale scores in patients with acute ischemic stroke

A multicenter, stratified, randomized, double-blind, placebo-controlled study to evaluate neurologic function and disability in patients with acute ischemic stroke given tissue plasminogen activator plus YM872 or tissue plasminogen activator plus placebo.

BRISTOL-MYERS SQUIBB: A double-blind, placebo-controlled, multicenter study of safety, efficacy and dose response in acute stroke.

Blockade of the GP IIB/IIIA Receptor to Avoid Vascular Occlusion (BRAVO). A Double-Blind, Placebo- Controlled, Parallel-Group, Dose-Response Study to Evaluate Efficacy and Safety

PARK-DAVIS: A double blind, placebo-controlled, parallel-group, 3 day treatment and 3 month follow-up, multicenter study of intravenous FOSPHENYTOIN in patients with acute ischemic stroke.

MS Clinical Trials Experience

BiogenIdec: 109MS301: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis

TEVA/LEMMON Company: Long-term, open label study to evaluate the safety of COPOLYMER 1 in patients with relapsing-remitting Multiple Sclerosis.

Novartis Pharmaceuticals Protocol No.: CFTY720DUS01

A 6-month, Randomized, Active Comparator, Open-label, Multi- Center Study to Evaluate Patient Outcomes, Safety and Tolerability of Fingolimod 0.5 mg/day in Patients with Relapsing Forms of Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy (EPOC)

BiogenIdec: 109MS303: A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with Relapsing-Remitting Multiple Sclerosis.

Migraine Clinical Trials Experience

AMDC-104-202: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Outpatients with Migraine Headache.

Phase III, "A Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine

Premere™ PFO Closure System for the Effect of Septal Closure of Atrial PFO on Events of Migraine with Remere (ESCAPE Migraine) Trial.

Neuropathy Clinical Trials Experience

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Trial of Fidarestat (SNK-860) in Patients with Diabetic Polyneuropathy.

MEM-MD-006" Evaluation of the Safety and Efficacy of Memantine in the Treatment of Chronic Pain in Patients with Diabetic Neuropathy

A Double-Blind, Placebo-Controlled Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of Compound versus Placebo in the Relief of Pain in Diabetic Peripheral Polyneuropathy."

A Randomized, Double Blind, Parallel Group Study of the Safety and Efficacy of Latranal Compared to Doxepin Cream and Placebo in Patients with Chronic Low Back Pain.

Epilepsy Clinical Trials Experience

A Randomized, Double-Blind, Parallel Group, Monotherapy Study to Compare the Safety and Efficacy of Two Doses of Topiramate in the Treatment of Newly Diagnosed or Recurrent Epilepsy

Elan Pharmaceutical: A Double-Blind, Randomized, Multicenter, Parallel Group Study to Establish Dose-Response, Safety and Efficacy of Zonisamide (Zonegran™) as Monotherapy in Patients With Newly Diagnosed Epilepsy.